Kythera Biopharmacueticals has appointed Hospira’s CEO Michael Ball to the company’s board of directors.
Ball has served as CEO at Hospira, creators of the first biosimilar to be launched in the EU, since 2011.
He joined the company following a 16-year stint at Botox developers Allergan, serving as president from 2006. His earlier roles at Allergan included president of pharmaceuticals and president for North America.
This experience in aesthetic products such as Botox will serve him well in his role at Kythera, with the company currently developing ATX-101 as an injectable treatment for the reduction of fat under the chin and around the neck. The drug is currently in phase III development.
“We are thrilled to have him on board,” commented Keith Leonard, Kythera’s president and CEO. “His knowledge and perspective will support our mission to bring innovation to the growing area of aesthetic medicine.”